News

Enrollment into the DAPT study was initiated in the US in October 2009 and in the EU in May 2010. HCRI said that the DAPT study is a

SuperGen posted a net income of $3.89m for the third quarter 2010, or $0.06 per diluted share, compared to $833,000 or $0.01 per diluted share, for the comparable

GLA is a toll-like receptor 4 (TLR-4) agonist which IDC has advanced into early clinical stage development. As per the terms of the license agreement, IDC will grant

The challenge study, in which 84 adults completed the challenge after receiving two doses of the vaccine or placebo, showed that the vaccine was generally well tolerated, and

Trius said that Torezolid phosphate (TR-701) is currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI). Trius has licensed patents

With this acquisition, Three Rivers is expected to serve as the commercial and operational cornerstone for Kadmon. Three Rivers is known to currently market several products for the

Adjusted net income decreased 14% to $1,313m for the third quarter of 2010, compared to $1,518m for the third quarter of 2009. The decrease in adjusted net income

Ofatumumab is a novel human monoclonal antibody. It targets a part of the CD20 molecule on B-cells encompassing an epitope on the small and large loops. In the

As per the terms of the option agreement, Celtic Therapeutics has an exclusive option to acquire and license rights to Resolvyx’s RX-10045, in all eye indications. Additionally, Celtic